Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03566693 · ClinicalTrials.gov registry record · NA

Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)

A NA study of Diabetes Mellitus, Type 2, sponsored by DexCom.

Completed
Registry status
NA
Development phase
176
Enrollment target
15
Study locations

NCT03566693: Completed NA study of Diabetes Mellitus, Type 2, sponsored by DexCom.

NCT03566693 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by DexCom. The registered enrollment target is 176 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03566693, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by DexCom.

COMPLETED
Registry status
NA
Development phase
176 participants
Enrollment target
15
Study locations

Study Summary

A study to compare the glycemic and quality of life benefits of diabetes management using Dexcom G6 continuous glucose monitoring (CGM) or self-monitored blood glucose (SMBG) made by study participants and their primary care physicians. Decisions will be based on insights from real-time use and retrospective insights, determined during remote visits. Participants will have type 2 diabetes and be using basal insulin (with or without oral medications and/or Glucagon-Like-Peptide-1 (GLP-1) analogue) and have an elevated Hemoglobin A1C (HbA1c).

Primary Outcome

Phase 1: Between group differences (CGM and SMBG) for the change in HbA1c (from Central Lab) from baseline to Month 8

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DEVICE Blood glucose meter
  • DEVICE Dexcom G6 CGM System

Study Locations (15)

North Carolina

  • University of North Carolina - Chapel Hill
  • Carteret Medical Group - Morehead City
  • Lucas Research / Diabetes & Endocrinology Consultants, PC - Morehead City

California

  • Keck School of Medicine @ USC - Los Angeles
  • Scripps Whittier Diabetes Institute - San Diego

Michigan

  • University of Michigan Internal Medicine - Ann Arbor
  • Henry Ford Medical Center - Detroit

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern Memorial - Chicago

Iowa

  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Minnesota

  • Park Nicollet International Diabetes Center - Minneapolis

Missouri

  • Washington University Barnes Jewish Hospital - St Louis

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2018-07-30
Est. Completion 2021-01-04
Phase NA
DexCom

26 total trials

What the finished NCT03566693 record still lists

NCT03566693 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Blood glucose meter is the first listed.

NCT03566693 lists 15 locations in 11 states (North Carolina, California, Michigan).

Frequently Asked Questions

What is clinical trial NCT03566693 about?

NCT03566693 is a clinical study titled "Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)". A study to compare the glycemic and quality of life benefits of diabetes management using Dexcom G6 continuous glucose monitoring (CGM) or self-monitored blood glucose (SMBG) made by study participants and their primary care physicians. Decisions will be based on insights from real-time use and retr...

What is the current status of trial NCT03566693?

This trial is currently completed. It is a NA study. The enrollment target is 176 participants. The study started on 2018-07-30. Estimated completion is 2021-01-04.

What conditions does trial NCT03566693 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT03566693?

The interventions under investigation include: Blood glucose meter (DEVICE), Dexcom G6 CGM System (DEVICE).

Who is sponsoring clinical trial NCT03566693?

This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03566693 being conducted?

This trial has 15 study locations across California, Georgia, Illinois, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03566693's enrollment target sits among peer trials

176 162nd of 348 higher than 187 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03304821 · 176 participants · Phase 2

    Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

  • NCT03447938 · 176 participants · NA

    The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

  • NCT03824145 · 176 participants · NA

    Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

  • NCT04177914 · 176 participants · Phase 3

    HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03566693, the US trial registry maintained by the National Library of Medicine. NCT03566693 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.